Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Peginterferon Alfa-2a Plus Ribavirin in Patients With Genotype 2 Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose Stratified by Rapid Virologic Response
Sponsor: Department of Health, Executive Yuan, R.O.C. (Taiwan)
This PHASE4 trial investigates Chronic Hepatitis C and is currently completed. Department of Health, Executive Yuan, R.O.C. (Taiwan) leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Department of Health, Executive Yuan, R.O.C. (Taiwan)
- National Science and Technology Council, Taiwan
- National Taiwan University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .